U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market Expected to Reach USD 10.2 Billion in 2020

According to a new market report published by Transparency Market Research “U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” the U.S., Europe and Japan orthopedic soft tissue surgical procedures market was valued at USD 7.3 billion in 2013 and is estimated to reach a market worth of USD 10.2 billion in 2020 growing at a CAGR of 4.9% from 2014 to 2020.

Browse the full U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market report at http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html

The report on U.S., Europe and Japan orthopedic soft tissue surgical procedures market studies market size of rotator cuff repair, vaginal prolapse, lateral epicondylitis, achilles tendinosis repair, gluteal tendon repair and anterior cruciate ligament reconstruction (ACL). Rising number of sport related injuries coupled with growth of active aging population in the developed regions would boost the demand of orthopedic soft tissue surgeries. According to the American Academy of Orthopaedic Surgeons (AAOS) and the American Orthopaedic Society for Sports Medicine, over 150,000 anterior cruciate ligament (ACL) injuries occur each year in the U.S. alone. Additionally, introduction of high cost and innovative surgical repair products and increasing incidence of obesity have raised the demand of orthopedic surgeries thereby propelling market growth. For example, Biomet, Inc. launched JuggerKnotless Soft Anchor device in July 2014 which featured company’s all-suture anchor technology. This device enables the repair of rotator cuff damage with better restoration and high efficacy. Growing acceptance of minimally invasive soft tissue surgical techniques (arthroscopy procedures) has enabled the completion of soft tissue surgeries in shorter time with lesser complication rates. This factor is also increasing the uptake of soft tissue surgeries. However, asymptomatic nature of soft tissue surgeries and high threat from conservative therapy are anticipated to restrain the market growth.

In terms of various surgical procedures ACL reconstruction accounted for the largest share of the market in 2013. ACL reconstruction is also likely to retain its dominant position in the future as it is the most common knee injury that requires surgical intervention. Rising participation in sports such as football, basketball and others along with increasing number of patients opting for reconstructive surgeries due to introduction of minimally invasive surgeries would fuel the growth of this segment. Similarly, launch of bio-absorbable which nullifies the risk related to implant removal would also aid in increasing the market size for ACL reconstruction. The market of gluteal tendon repair accounted for the smallest share in 2013 owing to large pool of patients being treated by non-operative methods such as pain killers and steroid injection for this condition.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/us-soft-tissue-repair-sports-medicine.htm

soft-tissue-repair-sports-medicine-market

Geographically, the U.S. orthopedic soft tissue surgical procedures market captured major market revenue in 2013 and is expected to dominate the market during the forecast period from 2014 to 2020. Rising population base, increasing urge to stay healthy among geriatric population and improving healthcare coverage would contribute towards the growth of orthopedic soft tissue surgical procedures in this region. The orthopedic soft tissue surgical procedures market in Europe is anticipated to grow at a CAGR of 4.7% due to increasing number of sports related injuries. According to “Injuries in the European Union” published by EuroSafe, sports related injuries accounted for around 14% of the total injuries in the European Union. Similarly, a survey conducted by the professionals in Europe in 2010 concluded that the annual prevalence of people consulting for shoulder pain was 2.4% in the U.K.; most of these were attributed to rotator cuff injuries. Thus, increasing incidences of soft tissue injuries would propel the market growth in this region.

The orthopedic soft tissue surgical procedures market is fragmented in nature and is dominated by players, namely Arthrex, Inc., Smith & Nephew, plc., DePuy Synthes, Inc., Stryker Corporation., CONMED Corporation, and ArthroCare Corporation. Of all these, Arthrex was identified as the largest player in this market in 2013 followed by Smith & Nephew and Depuy Synthes, Inc.

The U.S., Europe and Japan orthopedic soft tissue surgical procedures market is segmented as follows:

U.S. Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Europe Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Japan Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1768

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Dilated Cardiomyopathy Therapeutics Market Expected to Reach USD 0.33 billion Globally in 2020

According to a new market report published by Transparency Market Research "Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global dilated cardiomyopathy market was valued at USD 651.0 million in 2013 and is estimated to reach USD 328.6 million in 2020 declining at a CAGR of (7.0%) from 2014 to 2020.

Browse the full report Dilated Cardiomyopathy Therapeutics Market at http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Dilated cardiomyopathy (DCM) is one of the myocardium disorders associated with cardiac dysfunction. Hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathies represent the four major types of cardiomyopathies, and the others fall under unclassified category. DCM accounts for one of the major causes of heart failure and is characterized by the presence of dilated heart muscles which lead to enlargement of the heart. This in turn, hampers blood pumping capacity of the heart and with time, DCM spreads to the right ventricle, atria and ultimately results in heart failure. The occurrence of dilated cardiomyopathy in males is more prevalent than in females at a ratio of 3:1. Patients with mild DCM can lead normal lives by regular intake of medication along with some lifestyle changes, while patients with severe DCM need a heart transplant.

Oral medications and implantable medical devices constitute the key treatment options for DCM. Oral medications decrease the size of the heart by acting against high blood pressure and coronary artery disease. Devices implanted in DCM patients refer to implantable cardioverter–defibrillator (ICD), pacemakers (biventricular pacing) and heart pumps. The dilated cardiomyopathy therapeutics market is anticipated to decline throughout the forecast period from 2014 to 2020. This is majorly attributed to patent expirations, potential side effects of the drugs and increasing efficiency of alternative therapies.

The market for dilated cardiomyopathy therapeutics is segmented majorly by drug class and geography. The various drug classes considered include aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and beta blockers. ACE inhibitors are considered as the first line of treatment in patients suffering from dilated cardiomyopathy, and these drugs help improve pumping capacity of the heart by decreasing the activity of rennin-angiotensin-aldosterone system (RAAS). The sales of ACE inhibitors are anticipated to reduce during the forecast period from 2014 to 2020 majorly due to patent expiration of the prominent drugs and increasing competition from generic drugs, which will further hamper market growth.

Aldosterone antagonists reduce cardiac activity and blood pressure. Eplerenone and spironolactone are the two major aldosterone antagonists used in the treatment of dilated cardiomyopathy. This drug class will record highest growth rate owing to their increased acceptance and increased survival rate of patients with DCM. Angiotensin II receptor blockers (ARBs) in combination with ACE inhibitors are usually preferred to treat dilated cardiomyopathy as these drugs block the RAAS pathway, thereby reducing the pressure exerted by the heart. Clinical trials have proven the successful effect of ARBs such as valsartan, losartan and candersartan against DCM. However, loss of patent exclusivity of major drugs followed by the increased efficiency of combination therapies in treatment of DCM might hamper market growth and result in declined sales in the forthcoming years.

Currently, there is no drug approved specifically for the treatment of dilated cardiomyopathy; however, the above mentioned drugs have been studied for their effectiveness in treatment of DCM that has lead to doctors prescribing these medications. This factor provides lucrative opportunity for the market payers to develop and commercialize specific drugs against dilated cardiomyopathy. Increasing efficiency of alternative therapies such as implantable medical devices and gene therapy might further play a role in decelerating market growth.

Major players competing in this market are Novartis International AG, Merck Co. & Inc., and AstraZeneca plc that together accounted for more than 70% of the total dilated cardiomyopathy therapeutics market revenue. Other players include Pfizer, Inc., Sanofi Aventis, GlaxoSmithKline plc and Valeant Pharmaceuticals, Inc. Increasing investments by market players towards the development of dilated cardiomyopathy drugs will favor market growth post their approval. For instance, Array BioPharma, Inc. (ARRY – 797), Celladon Corporation (MYDICAR) and Vericel Corporation (IXCELL-DCM, Catheter-DCM, IMPACT-DCM) constitute some of the companies whose drugs are in pipeline (phase I or Phase II).

Browse the full Press Release report:

http://www.transparencymarketresearch.com/pressrelease/dilated-cardiomyopathy-market.htm

The global dilated cardiomyopathy therapeutics market is segmented into the following categories:

Dilated cardiomyopathy therapeutics market, by drug class

Aldosterone antagonists

Angiotensin-converting enzyme (ACE) inhibitors

Angiotensin II receptor blockers (ARBs)

Beta-blockers

Dilated cardiomyopathy therapeutics market, by pipeline drugs

ARRY-797

ixCELL-DCM

MYDICAR

OR-1

CAP-1002

Dilated cardiomyopathy therapeutics market, by geography

North America

Europe

Asia Pacific

Rest of the World (RoW)

Request a Brochure of this Report http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Active Pharmaceutical Ingredients Market Growing at a CAGR of 6.5% between 2014 and 2020

Diseases and epidemics are nature’s way to control population. With the ever-increasing number of deaths being reported due to various chronic diseases as well as newly diagnosed cases, the global active pharmaceutical ingredients (API) market has a huge demand to meet.

Browse Full Global Active Pharmaceutical Ingredients Market Report With Complete TOC @ http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

Global API Market to be Valued at US$185.9 Billion by 2020

In 2013, the global API market was valued at US$119.7 billion. It is expected to grow at a CAGR of 6.5% from 2014 to 2020 and reach a valuation of US$185.9 billion by 2020. On the basis of therapeutic area, the API market is segmented into non-steroidal anti-inflammatory drugs (NSAIDS), oncology drugs, anti-diabetic drugs, cardiovascular drugs, central nervous system drugs, musculoskeletal drugs, and others.

Oncology Segment Will Be the Fastest Growing Drug Segment

Due to the prevalent sedentary lifestyle and growing aging population, cardiovascular diseases and diseases related to the central nervous system are rising. In 2013, the market revenue share for cardiovascular drugs was the highest. As per the data provided by the World Health Organization, in 2012, cancer alone led to 8.2 million deaths worldwide along with 14 million newly diagnosed cases. In response to this, the oncology drug segment will have the fastest growth in the API market during the period from 2014 to 2020. High potency active pharmaceutical ingredients (HPAPIs) are a component of most drugs in the oncology drug segment. So, the growth of the HPAPI market would be rapid to keep up with the growth of oncology drug segment.

Asia Pacific will Account for the Highest Growth from 2014 to 2020

In 2013, North America accounted for the majority share (35%) in the global API market. The API market in this region is expected to grow further. FDA approvals for the production of innovative drugs and growing awareness about the intake of generic medicines have led to the growth of the API market in North America.

The Asia Pacific region is expected to achieve the highest growth in the global API market in the period from 2014 to 2020. The API market has a huge demand from the Asia Pacific region because of the population demographics in this geography. In terms of production, the global API market has shifted to Asia Pacific because of the availability of cheap labor, tax benefits provided by the governments for manufacturing, and less regulations on the markets.

China and India are the frontrunners in API production. API manufacturing companies from North America and Europe have invested substantially in these two countries. In North America, stringent pharmaceutical regulations, such as the U.S. Drug Quality and Security Act, have to be met with. This has caused a slight decrease in the growth of the API market in this region.

Browse Full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/active-pharmaceutical-ingredients.htm

Costlier Production of Biological Drugs Hampers Segment

Compared to synthetic APIs, biological drugs are costlier because they are difficult to replicate and have difficult manufacturing requirements. Enhanced technological support has resulted in the production of biosimilars, which are not the exact replication of innovator drugs, but are efficient and safe. This has led to a big opportunity for biopharmaceutical companies like Novartis in the API market.

However, production of biosimilars requires approvals from the respective countries. The European Union has set the trend by approving biosimilars and the WHO has followed the approval guidelines similar to the European Union. As a first, the U.S. has approved the biosimilar Filgrastim (2015), which shows its interest in expanding its biological API market.

Key Players in Active Pharmaceutical Ingredients Market

The key players competing in the global API market include Cambrex Corporation, Boehringer Ingelheim Group, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., BASF SE, Hospira Inc., Lonza Group, Mylan, Inc., Novartis AG, Actavis plc, Teva Pharmaceutical Industries Ltd., and Wuxi Apptec.

Request a Brochure of this Report

http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1690

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Tuberculosis Testing Market Expected to Reach USD 2.62 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Tuberculosis Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” the global tuberculosis testing market was valued at USD 1,936.1 million in 2013 and is expected to grow at a CAGR of 4.3% from 2014 to 2020, to reach an estimated value of USD 2,619.4 million in 2020.

Tuberculosis (TB) accounts for a large share of the global infectious disease burden. The disease was most widespread between 1950s and 1960s across the world and the WHO declared TB as a global emergency in 1993. However, due to the continuous and effective control measures and programs such as Stop TB and DOTS (Directly Observed Treatment, Short-course) most developed nations have been able to minimize the spread of this disease. Tuberculosis is still highly prevalent in many parts of the world affecting millions of lives, especially in Asia and Africa.

TB is a highly contagious disease and is the second leading cause of death, after human immunodeficiency virus (HIV). Active tuberculosis and latent tuberculosis are the two most common forms of TB that affect individuals. Over the time, TB has also developed into more diverse and potent forms that are referred as multi-drug resistant (MDR) or extensively drug resistant (XDR) TB. These conditions are also spreading at a rapid rate and require extensive diagnostic and treatment measures to check its spread worldwide. Various tuberculosis testing procedures and equipment are currently available in the global market. Improved and technologically advanced TB testing techniques such as IGRA, rapid TB tests, serological tests, etc. have made diagnosis more accurate, reliable, quick and easy to use.

Some of the major commercially available TB tests include culture tests, nucleic acid tests, tuberculin skin tests, sputum smear microscopy, chest X-ray and drug susceptibility testing. Culture-based TB tests were the largest segment in terms of revenue of the global TB testing market, valued at USD 691.2 million in 2013. Factors such as high sensitivity, accuracy and reliability of culture-based TB tests over other TB tests such as smear microscopy, Mantoux test and chest radiography have been attributed to the higher market share of the segment.

According to the WHO estimates, over nine million people suffered from tuberculosis in 2013 worldwide. The total number of TB cases increased by approximately 4.7% from 8.6 million cases in 2012 to 9 million in 2013 globally. The high prevalence and incidence of TB, availability of various new and improved tests, growing awareness levels, developing healthcare infrastructure and improving purchasing power of the general population are the major factors responsible for the growth of tuberculosis testing market. In addition, increased involvement of some of the world’s leading organizations such as the WHO and FIND (Foundation for Innovative New Diagnostics) for the development of new TB diagnostic tests is also responsible for the growth of the TB testing market. For instance, the WHO, through its Stop TB initiative, has provided the world with a vision to eradicate TB by 2050. On the other hand, factors such as lack of specificity, high cost associated with testing procedure and requirement of specialized equipment might hinder the growth of tuberculosis testing market. Besides these facts, the TB diagnostics market is observed to be a promising prospect in the near future as many new product developers and manufacturers are expected to venture into the market with a robust pipeline of testing technologies.

Geographically, the global market for tuberculosis testing has been segmented into four major markets, namely, North America, Europe, Asia Pacific, and Rest of the World (RoW). Asia Pacific accounted for a majority share, i.e. over 35% of the overall tuberculosis testing market in 2013. The major share of Asia Pacific is attributed to the presence of vast patient pool and very high incidence rate of TB. North America is the second largest market for tuberculosis testing in terms of revenue followed by Europe. Major Western European economies such as the U.K., Germany, France, Spain and Italy are the key contributing nations towards the overall tuberculosis testing market revenue in the region.

Browse the full Tuberculosis Testing Market (Smear Microscopy, Culture Based Tests, Nucleic Acid Testing, Mantoux Test, Radiography (Chest X-Ray), Drug Susceptibility Testing (DST) and Other TB Tests): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at http://www.transparencymarketresearch.com/tuberculosis-testing-market.html

Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche, Ltd., Hain Lifescience GmbH, bioMérieux SA, Hologic, Inc., QIAGEN, Akonni Biosystems, Inc., Abbott Laboratories, Alere, Inc., Cepheid, Epistem, Plc. and Sanofi are some of the major players operating in the global tuberculosis testing market. Among these Becton, Dickinson and Company or BD, Thermo Fisher Scientific, Inc, F. Hoffmann-La Roche Ltd. and Hain Lifescience GmbH dominate the global tuberculosis testing market.

 

The global tuberculosis testing market is segmented as follows:

Tuberculosis Testing Market, by Test Type

Smear Microscopy

Culture Based Tests

Nucleic Acid Testing

Mantoux Test (Tuberculin Skin Test)

Radiography (Chest X-Ray)

Drug Susceptibility Testing (DST)

Other Tests (Serological Tests, IGRA, ADA, etc.)

Tuberculosis Testing Market, by Geography

North America

Europe

Asia Pacific

Rest of the World (RoW)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2267

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

2020 Vision: The Near Future of Meningococcal Vaccines Market

According to a new report published by Transparency Market Research “Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,” the meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.

Browse the full Meningococcal Vaccines Market Report at http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 2,655.0 million by 2022 at a CAGR of 8.9%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.

Browse the full Press release Report :

http://www.transparencymarketresearch.com/pressrelease/meningococcal-vaccines-market.htm

The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

meningococcal-vaccines-market

The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type

Polysaccharide Vaccines, by Brand

Menomune

Mencevax

NmVac4

Others

Quadri Meningo

Bi Meningo

Conjugate Vaccines, by Brand

Menactra

Menveo

NeisVac-C

Nimenrix

Meningitec

Menjugate

MenAfriVac

Combination Vaccines, by Brand

MenHibrix

Menitorix

NmVac4-DT

Men B Vaccines, by Brand

Bexsero

Trumenba

Meningococcal Vaccines Market, by Geography

North America

U.S.

Canada

Europe

U.K.

Germany

Rest of Europe

Asia Pacific

Japan

Australia

Rest of Asia Pacific

Rest of the World

Latin America

Africa

Rest of RoW

Request a Brochure of this Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1666

 

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Pulmonary Arterial Hypertension (PAH) Market Expected to Reach USD 5.19 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Pulmonary Arterial Hypertension (PAH) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” the global PAH market was valued at USD 4.04 billion in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 5.19 billion in 2020.

Browse the full Pulmonary Arterial Hypertension (PAH) Market Report at http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

Pulmonary arterial hypertension (PAH) is a medical condition, characterized by restricted blood flow through the pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance and subsequently right heart failure. PAH is one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO). PAH occurs, when the pulmonary arteries become narrowed, thickened, or blocked. The advanced therapy to treat PAH includes prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. This advanced therapy is directed towards PAH itself, and not at the underlying cause of PAH. In addition to the aforementioned classes of drugs, physicians also prescribe drugs such as calcium channel blockers, diuretics, digoxin and anticoagulants to patients with PAH.

Based on the commercially-available drug classes, to treat PAH, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the first medications approved by the U.S. FDA for the treatment of PAH. Currently, epoprostenol (Flolan and Veletri), treprostinil (Remodulin, Tyvaso and Orenitram), and iloprost (Ventavis) are the three drugs under this category, which are widely used to treat patients with PAH. A new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016. This new drug is likely to drive growth of the prostacyclin and prostacyclin analogs market during the forecast period from 2014 to 2020.

pulmonary-arterial-hypertension-therapeutics-market

Endothelin receptor antagonists (ERAs) that inhibit the interaction between endothelin and endothelin receptors have emerged as one of the mainstays in the treatment of PAH. Tracleer (bosentan) is the first U.S. FDA approved ERA that is being used to treat PAH. Letairis/Volibris (ambrisentan) and Opsumit (macitentan) are the other approved ERAs for treating PAH. Of these, Opsumit was approved by the U.S. FDA and the European Commission in December 2013. Opsumit is expected to emerge as the most selling PAH drug by the end of 2020. Tracleer is set to go off-patent in the U.S. and Europe in 2015 and 2017, respectively. Patent expiry of Tracleer is likely to cause a huge set back in growth of the ERAs market during the forecast period from 2014 to 2020.

Revatio (sildenafil) from Pfizer, Inc. and Adcirca (tadalafil) from Eli Lilly/United Therapeutics Corporation are the two U.S. FDA approved PDE-5 inhibitors that are used to treat PAH. Adempas (riociguat) is the only approved sGC stimulator for the treatment of PAH. Adempas is designed to treat PAH by stimulating the nitric oxide receptor sGC, which induces vasodilation. Adempas was first approved by the U.S. FDA in October 2013. During the forecast period between 2014 and 2020, riociguat would face stiff competition from drugs such as macitentan and treprostinil (extended release tablet), as they all are meant for oral administration. The novel mode of action of riociguat would also play a key role in driving growth of this segment during the forecast period.

The global pulmonary arterial hypertension (PAH) market was dominated by players such as Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation in 2013. Actelion Pharmaceuticals, Ltd. accounted for the largest share of the overall PAH market in 2013, as one of its products, Tracleer (bosentan), was the bestselling PAH drug in 2013. During the forecast period from 2014 to 2020, Bayer HealthCare, which recently launched a new drug Adempas (riociguat), is likely to witness substantial growth in the PAH space. Arena Pharmaceuticals, Inc., Dong-A ST Co., Ltd., Reata Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis International AG, and Aires Pharmaceuticals, Inc. are some major companies with PAH drugs in their clinical pipeline.

The global PAH market is segmented as follows:

Global Pulmonary Arterial Hypertension Market, by Drug Class

Prostacyclin and Prostacyclin Analogs

Endothelin Receptor Antagonists (ERAs)

Phosphodiesterase-5 (PDE-5) Inhibitors

Soluble Guanylate Cyclase (sGC) Stimulators

Pipeline Analysis: Pulmonary Arterial Hypertension Market

Early-stage Drug Candidates (Phase I & Phase II)

Late-stage Drug Candidates (Phase III & Registration Phase)

Global Pulmonary Arterial Hypertension Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1181

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Foot and Mouth Disease Vaccines Market to Earn Highest Revenues from APAC, to Hit US$ 0.95 billion by 2020

A recent report by Transparency Market Research projects moderate growth within the global foot and mouth disease (FMD) vaccines market through 2020. The report, titled, Foot and Mouth Disease (FMD) Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020, predicts that the FMD vaccines market will chart a CAGR of 8.8% between 2014 and 2020. The FMD vaccines market approximated US$ 0.51 billion as of 2013 and will likely be worth US$ 0.95 billion by 2020, the study finds. The growing frequency of FMD outbreaks has necessitated the development of more effective vaccines to treat the disease; this is especially seen in endemic countries. The disease has been a gnawing concern for governments of several nations, prompting them to allocate more funding to eradicate the foot and mouth disease. The government’s role has helped raise levels of awareness about the foot and mouth disease in general and about the FMD vaccines available in particular, causing a higher demand for routine FMD vaccination.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Conversely, the market does face restraints in the form of unpredictable outbreaks of serotype. Governments are purchasing vaccines from private manufacturers, which, to some extent, limits the expansion of the FMD vaccines market.To study the market in detail, the report segments the foot and mouth disease vaccines market by type as: Conventional and emergency vaccines. The conventional FMD vaccines market has been further sub-segmented as: Aluminum hydroxide/saponin, and oil-based vaccines. The oil-based FMD vaccines segment held a 63% share in the overall FMD vaccines market as of 2013 thanks to its efficacy in treating the disease and its prolonged effect on different kinds of animals such as cattle, goat and sheep, and pigs.

The report also studies the market for FMD vaccines based on application types as: Cattle, sheep and goats, pigs, and others. The cattle segment was observed to be the largest application segment in the FMD vaccines market in 2013. This is ascribed to the high number of cattle reared worldwide, especially as the demand for milk and meat reaches unprecedented levels. The demand for FMD vaccines for cattle will be especially high in the Middle East-where pork consumption is prohibited. From the global standpoint as well, the cattle segment will exhibit the highest CAGR through the forecast period of this report.The four regions of North America, Asia Pacific, Europe, and Rest of the World have been studied comprehensively to offer a narrower overview of the regional market dynamics.

Browse the full Press Release Report : http://www.transparencymarketresearch.com/pressrelease/foot-mouth-disease-vaccines.htm

The findings of the report state that in 2013, the Asia Pacific region made up a whopping 70% share of the global FMD vaccines market. A high number of FMD endemic countries are present in this region, and outbreaks of FMD are still frequent here. Governments have been actively involved in the eradication of FMD diseases from their respective countries. Australia and New Zealand are exceptions to this because though they lie within the APAC region, the FMD disease is virtually non-existent here. Western Europe and North America are other geographical zones that are free of the FMD disease, which indicates practically no scope for the growth of the FMD disease market here.

The TMR report profiles FMD vaccine industry players such as Bayer AG, Agrovet Co., Brilliant Bio Pharma Limited, Biogenesis Bagó, and Indian Immunologicals Ltd.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2480

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com